Plandai Biotechnology, Inc. Announces Commencement of Human Bioavailability Study
April 14 2014 - 11:30AM
Marketwired
Plandai Biotechnology, Inc. Announces Commencement of Human
Bioavailability Study
Three-Month Study Will Compare Phytofare(TM) Against Green Tea
Extract
SEATTLE, WA--(Marketwired - Apr 14, 2014) - Plandaí
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutraceutical, and pharmaceutical, today announced that
it has received approval from the Ethics Committee at North West
University in Potchefstroom, South Africa to commence a human
clinical trial to test the oral bioavailability of its Phytofare™
Catechin Complex.
Phytofare™ is the trade name for live plant material extracts
that have undergone the Company's proprietary hydrodynamic sheering
process to rearrange the isomeric configuration of the molecules
into a format biocompatible with human tissues.
The study will compare the oral bioavailability -- meaning the
level of catechin absorption into the blood stream -- of Phytofare™
compared with green tea extracts that have not been processed as
well as Phytofare™ that has subsequently been further entrapped in
Pheroid®. The Company anticipates that the trial will
demonstrate that Phytofare™ and Phytofare™ entrapped in Pheroid®
have materially significant superior bioavailability, which should
provide the ability to deliver a clinical level of plant nutrients
as relatively low dosages. Plandaí believes that this will
unlock the health potential of not only green tea but also other
phytonutrients which suffer from low natural bioavailability.
According to the timeline provided by the University, the
recruitment of the participants is scheduled to start on the 14th
of April. The start date of the first leg, where the
bioavailability of the comparator will be determined, is scheduled
for the 11th of May. Final results from all three legs of the
trial should be available in July 2014. North West University,
located in Potchefstroom, South Africa, is considered one of the
finest research facilities on the continent.
Plandaí Chairman and Chief Executive Officer Roger Duffield
commented, "While we have exhaustively tested our Phytofare™ in
several applications, including the recently concluded topical
anti-aging study, the final piece for us is human
bioavailability. Many phytonutrients exhibit tremendous
potential in the lab for treating a host of medical and health
conditions, but low oral absorption renders them ineffective when
taken from the lab and into real world applications. At
Plandaí, we believe that nature has provided us with most of what
we need to combat everything from obesity to cancer to Alzheimer's
-- we just need to improve our bodies' ability to process these
nutrients. Phytofare will hopefully achieve that very
thing."
Plandaí's first product to market will be Phytofare™ Catechin
Complex, which includes the entire catechin profile derived from
live green tea that is grown and processed on the Company's 8,000
acre Senteeko estate in South Africa. Later in 2014, and
pending the results of a human clinical trial for treating cold and
flu symptoms, the Company will begin producing Phytofare™ Limonoid
Glycoside Complex, which contains citrus bioflavonoids.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly
bioavailable, phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandaí Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South Africa, to producing its patented
Phytofare™ extracts in-house, allowing the Company to guarantee the
continuity of supply as well as quality control throughout the
entire process. Targeted industries for the Company's products
include beverage, cosmeceutical, wellness, nutraceutical,
anti-aging, and pharmaceutical. For more information, please
visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandaí's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandaí is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact: Andrew Beyer Phone: 888-627-6902 Email:
investor@Plandaíbiotech.com
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Apr 2023 to Apr 2024